<SEC-DOCUMENT>0001193125-25-004097.txt : 20250110
<SEC-HEADER>0001193125-25-004097.hdr.sgml : 20250110
<ACCEPTANCE-DATETIME>20250110074743
ACCESSION NUMBER:		0001193125-25-004097
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20250110
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250110
DATE AS OF CHANGE:		20250110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Royalty Pharma plc
		CENTRAL INDEX KEY:			0001802768
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39329
		FILM NUMBER:		25520464

	BUSINESS ADDRESS:	
		STREET 1:		110 EAST 59TH STREET
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022
		BUSINESS PHONE:		(212) 883-0200

	MAIL ADDRESS:	
		STREET 1:		110 EAST 59TH STREET
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d921741d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:rprx="http://royaltypharma.com/20250110" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_EntityAddressStateOrProvince" name="dei:EntityAddressStateOrProvince" contextRef="duration_2025-01-10_to_2025-01-10">NY</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-267">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2025-01-10_to_2025-01-10">0001802768</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="rprx-20250110.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2025-01-10_to_2025-01-10"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-10</xbrli:startDate> <xbrli:endDate>2025-01-10</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-278">8-K</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 OR 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of The Securities Exchange Act of 1934</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2025-01-10_to_2025-01-10" format="ixt:datemonthdayyearen" id="ixv-279">January 10, 2025</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-280">Royalty Pharma plc</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact Name of Registrant as Specified in its Charter)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2025-01-10_to_2025-01-10" format="ixt-sec:edgarprovcountryen" id="ixv-281">England and Wales</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-282">001-39329</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-283">98-1535773</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or Other Jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of Incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(I.R.S. Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:50%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:48%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-71">110 East 59<sup style="font-size:75%; text-align: center;margin:auto; vertical-align:top">th</sup> Street</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-284">New York</ix:nonNumeric>, <span style=" -sec-ix-hidden:Hidden_dei_EntityAddressStateOrProvince">New York</span> </span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-285">10022</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of Principal Executive Offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-286">(212)</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-287">883-0200</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2025-01-10_to_2025-01-10" format="ixt-sec:boolballotbox" id="ixv-288">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2025-01-10_to_2025-01-10" format="ixt-sec:boolballotbox" id="ixv-289">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2025-01-10_to_2025-01-10" format="ixt-sec:boolballotbox" id="ixv-290">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2025-01-10_to_2025-01-10" format="ixt-sec:boolballotbox" id="ixv-291">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br/>Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-292">Class&#160;A Ordinary Shares, par value $0.0001 per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-293">RPRX</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2025-01-10_to_2025-01-10" format="ixt-sec:exchnameen" id="ixv-294">The Nasdaq Stock Market LLC</ix:nonNumeric></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2025-01-10_to_2025-01-10" format="ixt-sec:boolballotbox" id="ixv-295">&#9744;</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act. &#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;2.02</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Results of Operations and Financial Condition </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;10, 2025, Royalty Pharma plc issued a press release providing a preliminary update on the year ended December&#160;31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form <span style="white-space:nowrap">8-K.</span></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information included in Item 2.02 of this Current Report on Form <span style="white-space:nowrap">8-K,</span> including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that Section and shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;9.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:93%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;text-align:center">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;text-align:center">No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Description</td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d921741dex991.htm">Press release issued by Royalty Pharma plc, dated January&#160;10, 2025</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
</table> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURE </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:3%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:45%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3">ROYALTY PHARMA PLC</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: January&#160;10, 2025</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Terrance Coyne</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Terrance Coyne</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Chief Financial Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d921741dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g921741g49c07.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">


<IMG SRC="g921741g88j88.jpg" ALT="LOGO">
</TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ROYALTY PHARMA TO HIGHLIGHT ACCOMPLISHMENTS AND PROVIDE BUSINESS UPDATE AT 43rd ANNUAL J.P.
MORGAN HEALTHCARE CONFERENCE </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2024 Portfolio Receipts expected to be approximately $2,800&nbsp;million, at the upper end of guidance range
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Exciting development-stage pipeline with potential for peak royalties of &gt;$1.2&nbsp;billion; multiple key
upcoming events, including Phase 3 results for pelacarsen </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Royalty Pharma to benefit from new product launches in 2025, including Servier&#146;s Voranigo, Bristol Myers
Squibb&#146;s Cobenfy, Ascendis&#146; Yorvipath, Syndax and Incyte&#146;s Niktimvo and Geron&#146;s Rytelo </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NEW YORK, NY,
January</B><B></B><B>&nbsp;10, 2025</B> <B>-</B> Royalty Pharma plc (Nasdaq: RPRX) today provided an update on its business performance, including recent key accomplishments, and the full year 2024 outlook for Portfolio Receipts. Pablo Legorreta,
Royalty Pharma&#146;s founder and Chief Executive Officer, will discuss these updates on January&nbsp;14, 2025 as part of a webcast presentation to be held at 6:45 p.m. Eastern Time / 3:45 p.m. Pacific Time at the 43rd Annual J.P. Morgan Healthcare
Conference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Royalty Pharma delivered another year of strong performance in 2024,&#148; said Pablo Legorreta. &#147;We expect to achieve Portfolio
Receipts of approximately $2.8&nbsp;billion, based on continued double-digit growth in Royalty Receipts. We deployed approximately $2.8&nbsp;billion of capital in royalty transactions, including another record year for synthetic royalty deals. We
strengthened our development-stage pipeline, which now has the potential to add over $1&nbsp;billion in new royalties from innovative therapies across a diverse range of therapeutic categories. We have also today announced transformative steps to
enhance shareholder value through the acquisition of our external manager and a substantial increase of our commitment to share repurchases. I remain highly confident that Royalty Pharma is well positioned to deliver attractive, compounding growth
over the foreseeable future.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Strong 2024 Financial Performance </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on preliminary unaudited fourth quarter 2024 results, Royalty Pharma now expects to deliver Portfolio Receipts for full year 2024 of approximately
$2,800&nbsp;million, which is at the upper end of its previous guidance range of $2,750&nbsp;million to $2,800&nbsp;million. This represents anticipated underlying growth of approximately 13% year-over-year in Royalty Receipts, our recurring cash
inflows, and reflects the strong performance of Royalty Pharma&#146;s diversified royalty portfolio. Adjusted EBITDA <FONT STYLE="white-space:nowrap">(non-GAAP)</FONT> for full year 2024 is expected to be approximately $2,560&nbsp;million to
$2,570&nbsp;million and Portfolio Cash Flow <FONT STYLE="white-space:nowrap">(non-GAAP)</FONT> is anticipated to be approximately $2,450&nbsp;million to $2,455&nbsp;million. Net cash provided by operating activities is projected to be approximately
$2,760&nbsp;million to $2,770&nbsp;million for full year 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Royalty Pharma&#146;s preliminary unaudited fourth quarter 2024 results provided in this
press release are subject to change in connection with the completion of the company&#146;s final adjustments and other developments that may arise during the preparation and audit of its financial statements. Royalty Pharma&#146;s management will
host a conference call to discuss Royalty Pharma&#146;s fourth quarter and full year 2024 results in February 2025. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g921741g0110050724762.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g921741g49c07.jpg" ALT="LOGO" STYLE="width:4.58819in;height:0.529861in;">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">


<IMG SRC="g921741g88j88.jpg" ALT="LOGO" STYLE="width:1.72292in;height:0.370833in;">
</TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Capital Deployment Added Further Innovative Therapies, Enhancing Prospects </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since 2020, Royalty Pharma has announced transactions of approximately $15.5&nbsp;billion, including approximately $2.8&nbsp;billion in 2024. Important
additions to Royalty Pharma&#146;s portfolio in the past year include royalties on Voranigo, the recently <FONT STYLE="white-space:nowrap">FDA-approved</FONT> novel therapy for certain forms of brain cancer, as well as the potentially
practice-changing, development-stage compound frexalimab for multiple sclerosis. Royalty Pharma again recorded a record year for synthetic royalties with announced transactions of $925&nbsp;million, including Rytelo for myelodysplastic syndromes,
Niktimvo for chronic graft-versus-host-disease and Yorvipath for hypoparathyroidism. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2025, Royalty Pharma will benefit from several new product
launches, including Voranigo, Yorvipath, Niktimvo, Rytelo and Cobenfy for schizophrenia. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Development-Stage Pipeline Provides Exciting New Royalty
Opportunities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Royalty Pharma&#146;s pipeline of potential royalties on over 40 projects achieved important milestones in 2024, including the FDA
approvals of Cobenfy for schizophrenia, Tremfya for ulcerative colitis and Voranigo for brain cancer. Based on sell-side analysts&#146; consensus sales forecasts and marketer guidance, the potential therapies in Royalty Pharma&#146;s late-stage
pipeline have the combined potential to achieve <FONT STYLE="white-space:nowrap">un-risk</FONT> adjusted peak sales in excess of $21&nbsp;billion per year, which could translate to a potential of $1.2&nbsp;billion annually in new royalties to
Royalty Pharma. These include aficamten for obstructive hypertrophic cardiomyopathy, which has a U.S. Prescription Drug User Fee Act target action date of September&nbsp;26, 2025, and pelacarsen, which targets elevated Lp(a) in cardiovascular
disease and for which topline results are expected in 2025. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Webcast of J.P. Morgan Healthcare Conference </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Royalty Pharma will present at the 43rd Annual J.P. Morgan Healthcare Conference at 6:45 p.m. ET / 3:45 p.m. PT on January&nbsp;14, 2025. The webcast will be
accessible from Royalty Pharma&#146;s &#147;Events&#148; page at <U><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">https://www.royaltypharma.com/investors/news-and-events/events</FONT></FONT></U>. The webcast will also be archived
for a minimum of thirty days. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Royalty Pharma plc </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry,
collaborating with innovators from academic institutions, research hospitals and <FONT STYLE="white-space:nowrap">non-profits</FONT> through small and <FONT STYLE="white-space:nowrap">mid-cap</FONT> biotechnology companies to leading global
pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the <FONT STYLE="white-space:nowrap">top-line</FONT> sales of many of the industry&#146;s leading therapies. Royalty
Pharma funds innovation in the biopharmaceutical industry both directly and indirectly &#150; directly when it partners with companies to <FONT STYLE="white-space:nowrap">co-fund</FONT> late-stage clinical trials and new product launches in exchange
for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma&#146;s current portfolio includes royalties on more than 35 commercial products, including Vertex&#146;s Trikafta, GSK&#146;s
Trelegy, Roche&#146;s Evrysdi, Johnson&nbsp;&amp; Johnson&#146;s Tremfya, Biogen&#146;s Tysabri and Spinraza, AbbVie and Johnson&nbsp;&amp; Johnson&#146;s Imbruvica, Astellas and Pfizer&#146;s Xtandi, Novartis&#146; Promacta, Pfizer&#146;s Nurtec
ODT and Gilead&#146;s Trodelvy, and 14 development-stage product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g921741g0110050724762.jpg" ALT="LOGO" STYLE="width:5.65556in;height:0.0208333in;">
 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g921741g49c07.jpg" ALT="LOGO" STYLE="width:4.58819in;height:0.529861in;">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">


<IMG SRC="g921741g88j88.jpg" ALT="LOGO" STYLE="width:1.72292in;height:0.370833in;">
</TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as
of the date of this document unless stated otherwise, and neither the delivery of this document at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any
time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This document contains statements that constitute &#147;forward-looking statements&#148; as that term is defined in the United States Private Securities
Litigation Reform Act of 1995, including statements that express the company&#146;s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect
historical facts. Examples include discussion of Royalty Pharma&#146;s strategies, financing plans, growth opportunities, market growth and plans for capital deployment. In some cases, you can identify such forward-looking statements by terminology
such as &#147;anticipate,&#148; &#147;intend,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;plan,&#148; &#147;seek,&#148; &#147;project,&#148; &#147;expect,&#148; &#147;may,&#148; &#147;will,&#148; &#147;would,&#148; &#147;could&#148; or
&#147;should,&#148; the negative of these terms or similar expressions. Forward-looking statements are based on management&#146;s current beliefs and assumptions and on information currently available to the company. However, these forward-looking
statements are not a guarantee of Royalty Pharma&#146;s performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, and other factors.
Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company&#146;s control and could cause its actual results to
differ materially from those it thought would occur. The forward-looking statements included in this document are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such
statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information contained in this document relates to or is based on studies, publications, surveys and other data obtained from third-party sources and
the company&#146;s own internal estimates and research. While the company believes these third-party sources to be reliable as of the date of this document, it has not independently verified, and makes no representation as to the adequacy, fairness,
accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this document involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or
reliability of such assumptions. Finally, while the company believes its own internal research is reliable, such research has not been verified by any independent source. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For further information, please reference Royalty Pharma&#146;s reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may
get these documents by visiting EDGAR on the SEC website at <U>www.sec.gov</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Portfolio Receipts </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Portfolio Receipts is a key performance metric that represents our ability to generate cash from our portfolio investments, the primary source of capital that
we can deploy to make new portfolio investments. Portfolio Receipts is defined as the sum of Royalty Receipts and Milestones and other contractual receipts. Royalty Receipts includes variable payments based on sales of products, net of contractual
payments to the legacy <FONT STYLE="white-space:nowrap">non-controlling</FONT> interests, that are attributed to Royalty Pharma. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g921741g0110050724762.jpg" ALT="LOGO" STYLE="width:5.65556in;height:0.0208333in;">
 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g921741g49c07.jpg" ALT="LOGO" STYLE="width:4.58819in;height:0.529861in;">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">


<IMG SRC="g921741g88j88.jpg" ALT="LOGO" STYLE="width:1.72292in;height:0.370833in;">
</TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Milestones and other contractual receipts include sales-based or regulatory milestone payments and other
fixed contractual receipts, net of contractual payments to legacy <FONT STYLE="white-space:nowrap">non-controlling</FONT> interests, that are attributed to Royalty Pharma. Portfolio Receipts does not include proceeds from equity securities or
proceeds from purchases and sales of marketable securities, neither of which are central to our fundamental business strategy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Portfolio Receipts is
calculated as the sum of the following line items from our GAAP statements of cash flows: <I>Cash collections from financial royalty assets, Cash collections from intangible royalty assets, Other royalty cash collections, Proceeds from available for
sale debt securities </I>and <I>Distributions from equity method investees </I>less<I> Distributions to legacy <FONT STYLE="white-space:nowrap">non-controlling</FONT> interests&#151;Portfolio Receipts</I>, which represent contractual distributions
of Royalty Receipts, milestones and other contractual receipts to RPSFT and the Legacy Investors Partnerships. Distributions to RPSFT substantially ended in December 2023 when we acquired the remaining interest in RPCT held by RPSFT. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Use of <FONT STYLE="white-space:nowrap">Non-GAAP</FONT> Measures </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Adjusted EBITDA and Portfolio Cash Flow are <FONT STYLE="white-space:nowrap">non-GAAP</FONT> liquidity measures that exclude the impact of certain items and
therefore have not been calculated in accordance with GAAP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management believes that Adjusted EBITDA and Portfolio Cash Flow are important <FONT
STYLE="white-space:nowrap">non-GAAP</FONT> measures used to analyze liquidity because they are key components of certain material covenants contained within Royalty Pharma&#146;s credit agreement. Royalty Pharma cautions readers that amounts
presented in accordance with the definitions of Adjusted EBITDA and Portfolio Cash Flow may not be the same as similar measures used by other companies or analysts. These <FONT STYLE="white-space:nowrap">non-GAAP</FONT> liquidity measures have
limitations as analytical tools, and you should not consider them in isolation or as a substitute for the analysis of Royalty Pharma&#146;s results as reported under GAAP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The definitions of Adjusted EBITDA and Portfolio Cash Flow used by Royalty Pharma are the same as the definitions in the credit agreement. Noncompliance with
the interest coverage ratio, leverage ratio and Portfolio Cash Flow ratio covenants under the credit agreement could result in lenders requiring the company to immediately repay all amounts borrowed. If Royalty Pharma cannot satisfy these covenants,
it would be prohibited under the credit agreement from engaging in certain activities, such as incurring additional indebtedness, paying dividends, making certain payments, and acquiring and disposing of assets. Consequently, Adjusted EBITDA and
Portfolio Cash Flow are critical to the assessment of Royalty Pharma&#146;s liquidity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Adjusted EBITDA and Portfolio Cash Flow are used by management as
key liquidity measures in the evaluation of the company&#146;s ability to generate cash from operations. Management uses Adjusted EBITDA and Portfolio Cash Flow when considering available cash, including for decision-making purposes related to
funding of acquisitions, debt repayments, dividends and other discretionary investments. Further, these <FONT STYLE="white-space:nowrap">non-GAAP</FONT> liquidity measures help management, the audit committee and investors evaluate the
company&#146;s ability to generate liquidity from operating activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The company has provided reconciliations of these
<FONT STYLE="white-space:nowrap">non-GAAP</FONT> liquidity measures to the most directly comparable GAAP financial measure, being net cash provided by operating activities in Table 1. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g921741g0110050724762.jpg" ALT="LOGO" STYLE="width:5.65556in;height:0.0208333in;">
 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g921741g49c07.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">


<IMG SRC="g921741g88j88.jpg" ALT="LOGO">
</TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Royalty Pharma Investor Relations and Communications </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (212) <FONT STYLE="white-space:nowrap">883-6772</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>ir@royaltypharma.com </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Table 1 - GAAP to
<FONT STYLE="white-space:nowrap">Non-GAAP</FONT> Reconciliation (unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B><I>($ in millions)</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Full year 2024</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash provided by operating activities (GAAP)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">2,760&nbsp;-2,770</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from available for sale debt
securities<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19 - 21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Distributions from equity method
investees<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23 &#150; 25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest paid, net<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">110 &#150; 115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Development-stage funding payments - ongoing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1 &#150; 3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Distributions to legacy <FONT STYLE="white-space:nowrap">non-controlling</FONT> interests -
Portfolio Receipts<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(353 &#150; 364</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Adjusted EBITDA<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP> <FONT
STYLE="white-space:nowrap">(non-GAAP)</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2,560&nbsp;&#150;&nbsp;2,570</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest paid, net<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(110 &#150; 115</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Portfolio Cash Flow<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP> <FONT
STYLE="white-space:nowrap">(non-GAAP)</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2,450 &#150; 2,455</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Note: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Adjusted EBITDA is defined under the credit agreement as Portfolio Receipts minus payments for operating and
professional costs. Operating and professional costs reflect Payments for operating and professional costs from the GAAP statements of cash flows. Portfolio Cash Flow is defined under the credit agreement as Adjusted EBITDA minus interest paid or
received, net. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The table below shows the line item for each adjustment and the direct location for such line item on the GAAP
statements of cash flows. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Reconciling Adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Steatments of Cash Flows Clasification</P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Interest paid, net</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Operating activities <I>(Interest paid</I> less<I> Interest received</I>)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Distributions from equity method investees</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Investing activities</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Proceeds from available for sale debt securities</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Investing activities</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Distributions to legacy <FONT STYLE="white-space:nowrap">non-controlling</FONT> interests - Portfolio Receipts</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Financing activities</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g921741g0110050724762.jpg" ALT="LOGO">
 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>rprx-20250110.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 1/10/2025 5:44:43 PM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2024"
  xmlns:rprx="http://royaltypharma.com/20250110"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://royaltypharma.com/20250110"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2024/naics-2024.xsd" namespace="http://xbrl.sec.gov/naics/2024" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rprx-20250110_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rprx-20250110_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://royaltypharma.com//20250110/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>rprx-20250110_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 1/10/2025 5:44:43 PM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>rprx-20250110_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 1/10/2025 5:44:43 PM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://royaltypharma.com//20250110/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="rprx-20250110.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://royaltypharma.com//20250110/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g921741g0110050724762.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g921741g0110050724762.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  " A<# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "N,UW_D,W'_ ?_01117H9;_%?I^J
M.;%? O4SJ***]LX0HHHH V_"7_(SV?\ P/\ ] :BBBO$S+^*O3]6=V%^!^I_
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g921741g49c07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g921741g49c07.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#^17AI9@  34T *@    @ ! $[  (
M   1   (2H=I  0    !   (7)R=  $    B   0U.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $-H:7)A;FII
M8F5E($IE;F$    %D ,  @   !0  !"JD 0  @   !0  !"^DI$  @    ,T
M-   DI(  @    ,T-   ZAP !P  " P   B>     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                            ,C R-3HP,3HQ," P-3HQ,CHQ.  R,#(U
M.C Q.C$P(# U.C$R.C$X    0P!H &D <@!A &X :@!I &( 90!E "  2@!E
M &X 80   /_A"R-H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O #P_>'!A
M8VME="!B96=I;CTG[[N_)R!I9#TG5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED
M)S\^#0H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(CX\<F1F
M.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M
M<F1F+7-Y;G1A>"UN<R,B/CQR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2)U
M=6ED.F9A9C5B9&0U+6)A,V0M,3%D82UA9#,Q+60S,V0W-3$X,F8Q8B(@>&UL
M;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(B\^/')D
M9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](G5U:60Z9F%F-6)D9#4M8F$S9"TQ
M,61A+6%D,S$M9#,S9#<U,3@R9C%B(B!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"\B/CQX;7 Z0W)E871E1&%T93XR,#(U+3 Q+3$P
M5# U.C$R.C$X+C0T,#PO>&UP.D-R96%T941A=&4^/"]R9&8Z1&5S8W)I<'1I
M;VX^/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](G5U:60Z9F%F-6)D9#4M
M8F$S9"TQ,61A+6%D,S$M9#,S9#<U,3@R9C%B(B!X;6QN<SID8STB:'1T<#HO
M+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B/CQD8SIC<F5A=&]R/CQR9&8Z
M4V5Q('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^/')D9CIL:3Y#:&ER86YJ:6)E92!*96YA/"]R9&8Z
M;&D^/"]R9&8Z4V5Q/@T*"0D)/"]D8SIC<F5A=&]R/CPO<F1F.D1E<V-R:7!T
M:6]N/CPO<F1F.E)$1CX\+W@Z>&UP;65T83X-"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/#]X<&%C:V5T(&5N9#TG=R<_/O_; $, !P4%!@4$!P8%!@@'!P@*
M$0L*"0D*%0\0#!$8%1H9&!48%QL>)R$;'24=%Q@B+B(E*"DK+"L:("\S+RHR
M)RHK*O_; $,!!P@("@D*% L+%"H<&!PJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ
M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*O_  !$( #(!L@,!(@ "$0$#
M$0'_Q  ?   !!0$! 0$! 0           0(#! 4&!P@)"@O_Q "U$  " 0,#
M @0#!04$!    7T! @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S
M8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H
M:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZ
MPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 #
M 0$! 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  !
M G<  0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q
M%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X
M>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(
MR<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /I&
MBBB@ HHHH **** "BBO+?VA_^242?]?L/]:NG'GFH]Q2=E<]2HKYO^'OP*T;
MQCX#T[7;S5;ZWFNQ)NCB";5VR,@QD9Z+6MKW[.6AZ7X=U'4+?6M0:6TM9)T5
MU0J2JEL' 'I6[HTE+E<_P(YI-7L>]45XC^S/J=Y=^'=:LKFX>6"UN(VA5V)\
MO<K9 ]!\HX^OK6#IVE:S\1?C'XMTV?Q5JNFPZ?<3>2+>9MH59=@4+N  QZ4G
MA[3E%O8.?1-+<^C**\A_X49?_P#10]>_[[;_ .+K-^"FI:Q;?$;Q7X9O]8N]
M2L].>1(S=2%SNCF*;ADG;D=0/;TI>RBXN497L/F=[-'N%%>)?%'PUXH\):PG
MC7P3J.H36T4GFWFGM.\B1^K!,\QGG(_AZCC[M?6?CE=^*/#NGZ3X#L;@>)=4
M!CE15W?9.QVMT)/4-T4<G!IK#N23B[K\O47.D[,]UHKD/AWX+G\(:&%U34[K
M4]4N K7,T\[2*A_N(">%&>O4]3V YWXS>,+NQL[/PAX;9FU[776-/*<JT$9;
M&[(Z%CQGT#'M6:I\T^6+*<K*[/4:*\.^&GB#5/!7Q+U+P!XNU&:Z6=P]A=7+
ML=[X& "QZ.O;/WEQU->L>,)9(? VNRPNT<B:=<,CH<%2(VP0>QHG3<)*/<%*
MZN;-%>3_ +.NH7NI?#R^FU&[GNY5U610\\K.P'E1'&2>G)_.O6*FI#DDX]AQ
M=U<**\SU_P"$=_K>OWFI1>.=:L4N93(+:!V"1>P^8<5YA\/O#&L>,_%/B#2;
MGQGKELFDR%$DCN7)D^=EY!;C[M;1HPE%RYMO(AR:=K'TW17&>&OAZ=#T/5-+
MU#Q#JFKQZ@ #+<3,)(< CY&R2#SG/J!7FAU?Q'\#_&WD:Y>7VN>$]0(VW,Q+
MM$?8G.''=> PYZ])C24VU%Z_F-RMJT>_45X+J'B'Q#\:/&8TGP?=76E>&=/D
MS<ZC$S1M+[Y&#D\[4_$^WM^EZ;#I&EV]A:M*\4";5::0R.WJ68\DD\U-2GR)
M7>O8<9<VQ;HHKP+]J%V6/PQM8CFZZ'_KC12I^TFH!*7*KGOM%> >&OV?-,US
MPKI6K3:_J$4E]9Q7+1JBD*70,0/SK.\?_ RR\(>"+_7K+7KR>6S"-Y4J* ^Y
MU7J.GWL_A6JHTG+EY]?0CGE:]CZ0HKQKX:ZOJ%Y^SEK$]U>32SVMO>I#,TA+
MH%C)7#=>">/3BJ/P3^(VC:;X'N(?%OB1$O3?NR"]G9G\O9'C!.>,AOUJ70DE
M*VMG8?.M#W.BO*?B/\3O#%W\.]7@T'Q-;MJ+P@0"VE*R$[UZ$>V:WO@W=W%]
M\(]$N+V>6XG=9MTLKEV;$S@9)Y/ J'2E&'.^]BN9.5D=Q17F?QH\876D:+:^
M&] WMKFO.((!$V&C0D L,="2=H_$]JYGP-JVL_#GXHOX(\6:I)?VFIQ)+:7=
MP['$I7HI8G@D,F/55]351HN4.;\!.:3L>Y44'[IKY<^%F@_\)O8ZC-KOC;5=
M->UD1(U6_P!N\$$D_,?:E3I*<7)NU@E*S2/J.BOF_P"(OA&#P?X2;5=&^(&J
MWMTLR(L#:@#N!/)&TYXZUZS9:G>7GP'74I[B1KU_#[2M.&(<OY!.[/KGG/K5
M2HI14D[WT!2N[,[>BOFOX/\ Q2U30M0M].\87,\NC:J[?9K^\=F\F0?*1O/\
M.0 0>A(/ )S[)\1O'D/@CP\LT$?VO5+UO)T^T7DRR'O@<[1D=.I('>E.A.$^
M3<(S35SL**\3_9_U77=0UKQ=%XDO[JZNK>6%72>8N(WW3!PHS@<CMQP*]1\8
M>)[3P?X4O=:OF7;;QGRXR<>;(?NH/J?TR>U3.DX3Y-QQDG&YMT5\PV^H>-O!
M4F@?$37;R]N[/5+F1KNS,C;8XW^Z-I.!N4LR]AM6OI>QO;;4M/@O;&99K:XC
M66*13PRD9!IU:3IV=[H49<Q/1116)84444 %%%% !1110 4444 %%%% !111
M0 5Y;^T/_P DHD_Z_8?ZUZE7"_%_POJ7B_P$^EZ-#YUR;F.0+N5>!G/+$#OZ
MUK1:52+9,]8L\=\$>!_B9JG@&SU+PMXK%IISK*;>Q%[+&P*R,"  NT$L">N.
M><5RT.L^,]6UJ?PSXC\8WFD.^8)DU2YE6,GIL; . <]3QCO7TS\+]!OO#'PW
MTK1]5B\J[MA+YB;E;&Z5V'*DCHP[UD_%/X6:?X\TQKNWC\C6[=/W$\8&90/^
M6;Y(!'H2>/ID'LCB8^T:E:W<Q=-\J:)?A/\ #@_#O0KJ&YO%O+V]D629X@1&
MH4855SR>I.>.O3BO)M(\:V/PT^-WC*[\165\R7EQ,(EMXE+$--O5OF9>"O.:
M],^%FB^-_#$?]D>)&^UZ4B?N))70R0$=%!#DE?;''8XXKTDJ&^\ ?J*Q=3EG
M+F]ZY?+=*VECR#_AI;P=_P! W7/^_$/_ ,=K$^!<SZU\4/&/B*UMITTZ]>5X
MY)4Q@R3[U4XR-V.H!->]!%!R% /L*6H]K!1<8QM?S'RMM-L",C!Z5\]? :"&
M/XL>+ D2+Y2RK'A0-@\_H/0<#\J^A:*B%3EC*/<IQNTREK&K6FA:-=ZIJ,@B
MM;2(RR,?0=A[GH!W)KYV\,>&_'_Q&\03_$;2=1L-+N7G>.V:Y7=M4+LPBE&&
M #MSUR#WKZ6(R,'D4  # &!3IU?9IV6K%*/,]3YO^(7PS^)5[IQ\0:_K5AJ\
M^E1ET%I'Y<RH""2-L:YQ][D\<XY//HFA^-XO'?P-UB^9A]O@TNX@O8P,8E$+
M?,!Z,.1]2.U>F454J_-%)K82A9Z'S)\(/BYH/@'PC=:7K-KJ,T\U\]PK6L2,
MNTQQK@EG!SE#V]*]&T[]H;PEJ>J6MA;V&L++=3)"A>"(*&9@HSB3IDUZK13G
M5IS;DXZ^O_ !1DE:X5X5\"_^2E^._P#KX/\ Z.DKW6D"@$D  GKQ64:G+&4>
MY3C=IBUP'QPC5_@WKFY0Q40LN1G!\].17?T5,)<LE+L-JZL>?? R&.+X-Z*T
M<:HTAG=RJ@%V\YQD^IP ,^@%>@T443ES2<NX)65@KP#]J+_5^%_K=?\ M&O?
MZ\B^/'@7Q!XU30AX<L?M9M#<>=^^CCV[O+V_?89^Z>E;8:2C539%1-Q=CE?#
M_P *_B+?^&=,O-.\?3VEI<6<4L%NM[<*(D9 57 X& 0,#BK%_P# _P"(.JVA
MM-5\=F]MF(+0W%U<2(2.0=K<5[3X3L;C3/!FBV%ZGEW-KI\$,R9!VNL:JPR.
M#R#TK6JWB9J6EON$J<;'GEKX,B\!_!#6]%BN6NW73KN668KM#NT39P.<#  Z
M]J\]^!GP\\+>+? UW?\ B'24O;F/47A61I9%P@CC(&%8#JQ_.OH6BH5>2BUU
M?4KD5T>-_$OX5>"]"^&^LZGI.AQV]Y;PAHI1/*VT[U'0L1T-;_P@O[72_@3I
M-]J$RP6MO#/)+(_15$TA)KT1T612KJ&4]01D&D1%C0)&JHHZ!1@"I=9RAR2U
MUN'*E*Z/G'0- \:_%#Q9=?$'2=2M]*:&X:'3VNHM^V, @!5*L. W)_O$GK5W
MX@?"_P")&M:,=1UO7[+6I=,1I8(;>V$<I'&X*51<G SCVXYKZ#HK3ZS)2326
MA/LU;4X;X4^/(O'7@R*::1?[4LU$-]'WW8X?Z,!GZY':O'O@G\-?#WC;0]6F
M\16L[RP3+'$\<S1E05)Z#@\^M?35%2JW*I<BM?\  ?)>USY.USP%;?##QD#X
MNT277?#-Q)MANHY6C<#KU1@-X'53P<<$=OH*\U+1M6^$6J3>&)H9M.729XH1
M#TC"PD!,=5(&.#S77T45*[J6<MU_6P1ARWL>'?#7P58^./@ ND:H&B8WDTEO
M.%^:&0'AAZCD@CN"?K6E\+OAIK5IK/\ PD'Q!D-U?Z>@L],BDD#B&-!M#C''
M(^[WZD\FO7Z*)8B3YDNHU!:'BGP+_P"1\^(?_7^G_HV>LWXA_P!K?%SXD'PA
MX<DABT_0PTEQ<S F,S=#G@YP?D QUW'I7O@15)*J 3UP.M+3]O\ O'42U%R>
M[RGC&L_#OXJ^(-&FTG6/&>E7-C. LD)LT4$ @CD1 C! Z5!\$?%%]HVL7WPX
M\2_)=6#O]C)[X)+H#W'.]?;/M7MU%+V]X.,E^@<EG=,****YS0**** "BBB@
M HHHH **J;K_ /N0?F:-U_\ W(/S- %NBJFZ_P#[D'YFC=?_ -R#\S0!;HJI
MNO\ ^Y!^9HW7_P#<@_,T 6Z*J;K_ /N0?F:-U_\ W(/S- %NBJF^_'6.$_1C
M1YE]_P \(O\ ON@"W153S+[_ )X1?]]T>9??\\(O^^Z +=%5/,OO^>$7_?='
MF7W_ #PB_P"^Z +=%5/,OO\ GA%_WW1YE]_SPB_[[H MT54\R^_YX1?]]T>9
M??\ /",_\#H MT54\Z]_Y]5_[^"CSKW_ )]5_P"_@H MT54\Z]_Y]5_[^"CS
MKW_GU7_OX* +=%5/.O?^?5?^_@H\Z]_Y]5_[^"@"W153SKW_ )]5_P"_@H\Z
M]_Y]5_[^"@"W153SKW_GU7_OX*/M%Y_SX_\ D84 6Z*J?:+S_GQ_\C"C[1>?
M\^/_ )&% %NBJGVB\_Y\?_(PH^T7G_/C_P"1A0!;HJI]HO/^?'_R,*/M%Y_S
MX_\ D84 6Z*J?:+S_GQ_\C"C[1>?\^/_ )&% %NBJGVJY[V3?]_!1]JN?^?)
MO^^Q0!;HJI]JN?\ GR;_ +[%'VJY_P"?)O\ OL4 6Z*J?:KG_GR;_OL4?:KG
M_GR;_OL4 6Z*J?:KG_GR;_OL4?:KG_GR;_OL4 6Z*J?:KG_GR;_OL4?:YQUL
MY/P(- %NBJGVN;_GSE_,4?:YO^?.7\Q0!;HK&O=?ELIA&='U&?*[MT$.]1[9
M]>*K_P#"5R?]"_K'_@+6T:-22ND0YQ3LSH:*Y[_A*Y/^A?UC_P !:/\ A*Y/
M^A?UC_P%I_5ZG87M(]SH:*Y[_A*Y/^A?UC_P%JQ8>('OKV.W;1]2M@^?WL\&
MU%P">3^&*3H5$KM#52+-FBBBL2PHHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
LB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g921741g88j88.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g921741g88j88.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#^17AI9@  34T *@    @ ! $[  (
M   1   (2H=I  0    !   (7)R=  $    B   0U.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $-H:7)A;FII
M8F5E($IE;F$    %D ,  @   !0  !"JD 0  @   !0  !"^DI$  @    ,X
M,   DI(  @    ,X,   ZAP !P  " P   B>     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MK.8.UNC?W<'G^7Y4K^[<=M;'2KJ^FLP5=0M22< "=>?UJ>XN[>T4&ZN(H0>
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:%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45144671230416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jan. 10, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001802768<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan. 10,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Royalty Pharma plc<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">X0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39329<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1535773<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">110 East 59th Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(212)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">883-0200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Class&#160;A Ordinary Shares, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RPRX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MJ.W("[W7&W.^WEAWPQ\/,[IF"V9_SV8:6GZEDO"42<.5))JM1MXDO+J.+EQ
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M>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @ ]#TJ6F60>9(9 0  SP,  !,
M  !;0V]N=&5N=%]4>7!E<UTN>&ULK9--3L,P$(6O$F5;)2XL6*"F&V +77 !
M8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4'5%\% )5!TYB
M'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T<F^I>.EY&TWP39G
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M+GAM;%!+ 0(4 Q0    ( /0]*EH,!;G4[@   "L"   1              "
M :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( /0]*EJ97)PC$ 8
M )PG   3              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L!
M A0#%     @ ]#TJ6G5S/#%:!   GQ   !@              ("!#0@  'AL
M+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( /0]*EJ?H!OPL0(
M .(,   -              "  9T,  !X;"]S='EL97,N>&UL4$L! A0#%
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K  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  /T3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d921741d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com//20250110/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d921741d8k.htm">d921741d8k.htm</File>
    <File>rprx-20250110.xsd</File>
    <File>rprx-20250110_lab.xml</File>
    <File>rprx-20250110_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d921741d8k.htm": {
   "nsprefix": "rprx",
   "nsuri": "http://royaltypharma.com/20250110",
   "dts": {
    "inline": {
     "local": [
      "d921741d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "rprx-20250110.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/naics/2024/naics-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "rprx-20250110_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "rprx-20250110_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 22
   },
   "report": {
    "R1": {
     "role": "http://royaltypharma.com//20250110/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2025-01-10_to_2025-01-10",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d921741d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2025-01-10_to_2025-01-10",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d921741d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://royaltypharma.com//20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://royaltypharma.com//20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://royaltypharma.com//20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://royaltypharma.com//20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://royaltypharma.com//20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://royaltypharma.com//20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://royaltypharma.com//20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://royaltypharma.com//20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://royaltypharma.com//20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://royaltypharma.com//20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://royaltypharma.com//20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://royaltypharma.com//20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://royaltypharma.com//20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://royaltypharma.com//20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://royaltypharma.com//20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://royaltypharma.com//20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://royaltypharma.com//20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://royaltypharma.com//20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://royaltypharma.com//20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://royaltypharma.com//20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://royaltypharma.com//20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://royaltypharma.com//20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001193125-25-004097-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-25-004097-xbrl.zip
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M*+4#4:YN1Y*?:K>W$C7O&^$G0I(K/6"2_ S^OO*YB4L>Y52X.Y@<^!$SBNK
MVL;7P/WK,JDIAD.NU-? $U1OQ(KM/Y8=[4*GT"V0UC *Q)C)5^?)K$XEEZ(P
M98W1>_ /NH#?JD=I(I3GN)1'SE:<PDKU;^T4)ANWR<<%1$GNDRWS,7AYKNN0
M%E6:'-5.5;P$><='[TZ>M$X] -,> Q*[6C*F=^4A+1GZ:V5_NI2M(* )7Z_D
MC;@/G^&957(-7.P?0GZ9Y\\AF9DFP: AST=YNX%=W_3D0:9_PV_R6I[Q5HE_
M+92FP7]X]*10;$K_(Q! QRF5ODVG> TI]Q-B8:KI6@(:>$0#TAHQ+];\CI&K
M/EA#I@Z^YEAI'WA,D,D'"RQ98J\?F5S?2DYOFL3[]W?5DGM\HH . 8L&(F0D
M-#[@(0'B!S&:?$(!-H!7P,SJ)#NJEC.H]TQP?P#RE=S2P>9'A"X$<.<:9_[L
MF/,XUZA6RWFGY#B;YV%?C&F70I.S* H C0"AYR2&M^,L?Q(2:&,X@6%FWSY2
M*[\ GSZQ&TL@:ZC528 >@]VO>4L/[V9C=1W.<HWF@'E?B!XP0J-(BDARS!+T
MQ(CT6"#ND6M8B+R=M>7W ZY9'H,"!G)Q+VF4[)A;"]WG 6H*KD!M:!;ZP'4M
M@/'#.- T9")6P9@H$$75'YL1D@:B!_2RT8VP0\OI!D,,_0"BPG%:UH< 0]QC
M.TQ"<HR;57TEECX\-?S9:G@SB6FF<<YB0#47<&UDNG-+(YEW)TLMUBKM^9OD
M&OB%>8@X3.),]>P\<4^(H$>!5QJ0E=6P5:1W[;A2.5E4L!LXZ5D^DUG6DF?K
MX+DC;;E&0AL@1I8X),IL]'=B@$NE=)1 5<]NK>..^KY[3)J?.J14=@I0\3'Q
M^QM^U^.W"[K8 VJ'MY]!D8$V"W8'WMJW!-XI8:!K2YE%Y*[5\&Z%YMU2JN2G
M()\Y-))"?&UOI8I3L#U./>,W:=BB-%Q+AIH<#T^;,W%HB"6$3$_PBC>5BIKS
M+4G%6H@"!?->AH0I]-?9@ TDR<^7]GL'VY4EV^>;-+V$-+65BIE\$9ERWV1J
M(YDJLWQEW]NN3"5];BQ36P_1,@ZDC868A&@J6GF\%#5 &B#!<E?'0U__?M#;
M":,M9V WR%^L6.(2\7C5K= ;O$EI#P![ ^(%5*F7V:5^*@E?FUZ2HGB>]F2Q
MT1T/H=J^>J%]_1>@V"X2FND)5P,PEAB05S\"($("L@@SFMJ"69/TU>U8K@G8
MK74;NZ6>$>FGI^MKI5RCB7K  O6,7$E /)ZZ[PZH9.J01%22.QK$C/S+*> =
M3A+A94\L?;1?M9N-I%542J37"NXS2%3.-3K7G=^_\M6FF$B]MB<=K%\XJPJ=
MX1 S9U1K%=",X"==4N73OTA7"^\+^4SE%Z;)Q45S*9U>S/%KASXZPXSTQL0S
M>7KH\0N(/S,G^.:2XUP1\&;!H<9!;\FM%/=Z@#YUA ESJHC/^CRT)_-MFM(Y
M2MW$N1REO?53)OO([N,3DZI,*\,PP)0(S_3C+L^&CGFIEY]DC1;'7';E:'VG
MZ>S025_H/S/-PF[WZG*-U@J:KSD&D#;[T;1JVD:[BR&/'H@A=TN?=O\!9.*^
M\E*8\X7MGP& F 40ZP"(0V$BGU@Q4PL(EFPRX?M N-D_LO?@D4!FK&",@]]S
M&!J9$\+\H$2R.ZZ@'8@&#3U,BE+/'&;'ROAF$)]*7]GM)?_!L*N\3R=A5Q;0
M!3(A^ZHX;)/;[AO<9O^&K\W;C<YDNW-O;SD8V7 !B_A3QL?I,> V^#C!/1TK
M=!^AZ[W3P<0=@@!4R/IW-?/G)%U--,H&F5[ J$2#-S#AW-Z:_>3MOA!A;SZO
M]L-5Y[S5R3>O+B[.KKNM>OKE:\ZKN>[2Q!HQ7P%)BUFBQ3,S;<V&>!;%<4]*
M!:>T>+PGV]EKI;X>\M?M*CM,Q8$VIY>N0!\EF2V\#?-IHG": A2@T5B/R2U]
MV(9FO@I)<C,U46+)]=1#LG@3$1P,%8,&A =S($N"*J:@?JUJ-,>"L"3@0^MT
MQY%O+AR$1B/BK5AB5?0Y\Q@>S+%#EETS9*5 SD!-1Y.M_=E!P)SW8QER-< 9
MH,<PX#VN2:U6<%$5&X/?C*7$.\#)%6$8>>-C"X5,=F^7IA!]31Y.WE>5G*FR
M3AE"GB#8)Q[,,Q9TF'I#TU-;,S2C6D-8"P.#)\FT.$0*]QA6R] 98 K!41 8
M:]MCX$&"$?<)RF7).>GS@/GFNWMBK"S8QD@H9M ^:QNK&SI]A\A;.K0XV<<&
MR5C9RLF0!X=HOP6ZPO=@PHF*>_^%02T:& DX[?' #F4&ISJ=U,J%\<D=%'@
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MZ$:*"*FQM:_8;P$84#D.&NQ#)%4<>.Q\)B)5KUW_D<CAT-YV%,!DHUF#=12
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MN/H22/M:HK$'@[PZAYPQE"P%;":XK8C%VYNMS5(PG@N EX33)ET \=84T2#
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MJ+J>A$//CR1]%VQ\- .,"%[0X\/ I#$)E)I10 ZTJ(()<\44+"A$XK&,$U.
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M+H4G: CL*A-_)+J ,!0.)K09O^'2H[8M2F<CN(,5.;:11B\GY0>N/QAI'[Y
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M>\R:+/#' 37(_",X;/F[_JKOW^H8GK!9BC7SU;VT5>J[-B9OUC=3][*^M?&
MB=[^X.8$7S17K#<^5@+:1@(>TK@S]X,7_[#0-/>C'UJ*S/LQ\3<_GB3Z_''M
MV'\;;GGS:.#R:FH.*]H8?FQSL[&9"A']?L^W&1DJIGW;+T\N2S9C 206>^6>
MAVR '_1773?N_>%6DMJ'_A;KHW]^]6$*N,]*BRKW&>5.7-[3U<95U7F2J?03
ME44@]$KK+"&-C63X\E3]QA+JK*56TLO\+6S^CO1E!U<+!ZYZ*GWCY;WG+UJ5
M354/)D*9>IH",N_ES/%S(-&-T"ZOM>B'8G\()5C[!RH!]E;ITTI#@?Q7$Q -
M?7;7'N@AH1,<^S33G'IZLD,W1C$O,.\GHSPN]G1FCYL3ZRB,Q1>#%*7Q$;^<
M_?RUXY?NP?E>NW"^VX)QVK8 9C0K%3U5I?@?O?7K6/ X5<'4]"MVY'%%K_M!
M32ZJ8Z[T_/QPO2)4^L86K</+JNHP=@P4YL*& 69/Z:7?6 ^&W[[]&Z*71QTT
MU#T/WT@MW<I5I-;?L_$'E0MSIS/_R[;_C,G/"A3[),0[2=^Y6$6\7(3V_78Y
M+^U<AJCT\O@+7#P=G)\=_C]02P,$%     @ ]#TJ6G!O%(]  P  3PL  !$
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M6BF4$E=P)A17N> 2OG2,_X5SE2?P5DJ8>)@EFA;--19):W5IB\SF"RSYRQ<
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M)R[5D?Z[$_DIFOWU!77F/U!+ P04    " #T/2I:&:CRFKX$  !^*@  %0
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M6R$WP5%J!EA@GYO<'K%O]BE +/D'4$L! A0#%     @ ]#TJ6@#B\.98#P
M V4   X              ( !     &0Y,C$W-#%D.&LN:'1M4$L! A0#%
M  @ ]#TJ6MB5_6BX'0  V8X  !$              ( !A \  &0Y,C$W-#%D
M97@Y.3$N:'1M4$L! A0#%     @ ]#TJ6G!O%(]  P  3PL  !$
M     ( !:RT  ')P<G@M,C R-3 Q,3 N>'-D4$L! A0#%     @ ]#TJ6FD/
MC@!B!@  OD,  !4              ( !VC   ')P<G@M,C R-3 Q,3!?;&%B
M+GAM;%!+ 0(4 Q0    ( /0]*EH9J/*:O@0  'XJ   5              "
M 6\W  !R<')X+3(P,C4P,3$P7W!R92YX;6Q02P4&      4 !0!  0  8#P
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>d921741d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="rprx-20250110.xsd" xlink:type="simple"/>
    <context id="duration_2025-01-10_to_2025-01-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
        </entity>
        <period>
            <startDate>2025-01-10</startDate>
            <endDate>2025-01-10</endDate>
        </period>
    </context>
    <dei:EntityAddressStateOrProvince
      contextRef="duration_2025-01-10_to_2025-01-10"
      id="Hidden_dei_EntityAddressStateOrProvince">NY</dei:EntityAddressStateOrProvince>
    <dei:AmendmentFlag contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-267">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2025-01-10_to_2025-01-10"
      id="Hidden_dei_EntityCentralIndexKey">0001802768</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-278">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-279">2025-01-10</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-280">Royalty Pharma plc</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-281">X0</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-282">001-39329</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-283">98-1535773</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-71">110 East 59th Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-284">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-285">10022</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-286">(212)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-287">883-0200</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-288">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-289">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-290">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-291">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-292">Class&#160;A Ordinary Shares, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-293">RPRX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-294">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-295">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
